AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...
Tune into live earnings calls Now streaming directly on quote pages. Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results